{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:53:23Z","timestamp":1791176003689,"version":"4.1.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is a complex autoimmune disease mainly characterized by progressive fibrosis affecting the skin and internal organs. Although several immunosuppressive and targeted therapies are currently available, many patients continue to experience refractory manifestations. Intravenous immunoglobulin (IVIG) has been increasingly used as an adjunctive treatment in selected cases; however, its efficacy across different disease manifestations remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically evaluate the efficacy and safety of IVIG in patients with systemic sclerosis and to quantitatively synthesize available evidence regarding its effects on skin involvement, gastrointestinal manifestations, and inflammatory myopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis were conducted according to PRISMA 2020 guidelines. MEDLINE\/PubMed, Embase, LILACS, and the Cochrane Library were searched from January 1966 to May 2026. Studies evaluating IVIG in adult patients with systemic sclerosis were included. Randomized controlled trials, observational cohorts, pilot studies, and case series were eligible. Quantitative synthesis was performed using random-effects models and standardized mean differences (SMDs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies were included in the systematic review. Six studies provided sufficient quantitative data for the meta-analysis of skin involvement, three for gastrointestinal outcomes, and two for muscle outcomes. The most common indications for IVIG therapy were cutaneous fibrosis, inflammatory myopathy, gastrointestinal involvement, and refractory musculoskeletal manifestations. Meta-analysis demonstrated a significant improvement in skin involvement assessed by the modified Rodnan Skin Score (SMD \u22120.59, 95% CI \u22120.95 to \u22120.22; p = 0.0019; I\n                      <jats:sup>2<\/jats:sup>\n                      = 78.0%). Gastrointestinal manifestations also improved significantly (SMD \u22120.73, 95% CI \u22121.16 to \u22120.29; p = 0.0012; I\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). For inflammatory myopathies, a limited quantitative synthesis of two studies showed a significant reduction in creatinekinase levels (SMD \u22120.53, 95% CI \u22120.80 to \u22120.26; p &amp;lt; 0.001). Across studies, IVIG was well tolerated, and serious adverse events were uncommon.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IVIG was associated with improvements in several clinical outcomes, particularly in observational studies, including skin fibrosis, gastrointestinal manifestations, and inflammatory myopathies. However, the only randomized placebo-controlled trial did not demonstrate significant short-term improvement in skin involvement at its primary endpoint. The available evidence suggests a potential adjunctive role for IVIG in selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1949145","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:36:29Z","timestamp":1791174989000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of intravenous immunoglobulin in systemic sclerosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Joz\u00e9lio Freire","family":"de Carvalho","sequence":"first","affiliation":[{"name":"Institute of Health Sciences, Federal University of Bahia","place":["Salvador, Bahia, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Paulo Correia de","family":"Araujo","sequence":"additional","affiliation":[{"name":"Institute of Health Sciences, Federal University of Bahia","place":["Salvador, Bahia, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Danieli","sequence":"additional","affiliation":[{"name":"SOS Immunologia delle Malattie Rare e dei Trapianti, SOD Clinica Medica, Dipartimento di Medicina Interna, Azienda Ospedaliero Universitaria delle Marche","place":["Ancona, Italy"]},{"name":"Department of Clinical and Molecular Sciences, Marche Polytechnic University","place":["Ancona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[{"name":"Reichman University","place":["Herzelia, Israel"]},{"name":"Center for Autoimmune Diseases, Sheba Medical Center","place":["Ramat\u00a0Gan, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.61","article-title":"Intravenous immunoglobulin therapy in rheumatic diseases","volume":"7","author":"Bayry","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.05.003","article-title":"Regulation of immune cell metabolism by therapeutic normal IgG intravenous immunoglobulin","volume":"156","author":"Rambabu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2025.06.012","article-title":"Expanding the mosaic functions of intravenous immunoglobulin","volume":"156","author":"Danieli","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060111","article-title":"Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a pilot study","volume":"66","author":"Nacci","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B21","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140833","article-title":"Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis","volume":"42","author":"Poelman","year":"2015","journal-title":"J Rheumatol"},{"key":"B23","article-title":"Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis","volume":"33","author":"Clark","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev318","article-title":"Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis","volume":"55","author":"Raja","year":"2016","journal-title":"Rheumatol (Oxford)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.02.008","article-title":"Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature","volume":"16","author":"Sanges","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102431","article-title":"Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients","volume":"19","author":"Chaigne","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226665","article-title":"Treatment of severe swallowing dysfunction in systemic sclerosis with IVIG: role of antimuscarinic antibodies","volume":"11","author":"Mendoza","year":"2022","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead093","article-title":"Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration","volume":"62","author":"Matsuda","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103441","article-title":"Immunoglobulins in systemic sclerosis management. A large multicenter experience","volume":"22","author":"Tandaipan","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B30","first-page":"1528","article-title":"Intravenous or subcutaneous immunoglobulins as potential treatment for gastrointestinal, cutaneous and vascular involvement in systemic sclerosis: data from an Italian cohort of 65 patients","volume":"75","author":"Bonomi","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102981","article-title":"Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience","volume":"20","author":"Agostini","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05613-5","article-title":"Efficacy and safety of intravenous immunoglobulin therapy in systemic sclerosis: a systematic review","volume":"44","author":"Garrote-Corral","year":"2024","journal-title":"Rheumatol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152471","article-title":"Role of intravenous immunoglobulins in systemic sclerosis (SSc): A systematic literature review","volume":"68","author":"Koczanowski","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/23971983241273852","article-title":"Efficacy assessment of intravenous immunoglobulin for gastrointestinal involvement in systemic sclerosis using UCLA SCTC GIT: Case-based review","volume":"10","author":"Neto","year":"2024","journal-title":"J Scleroderma Relat Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1038\/s41598-023-42464-9","article-title":"Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis","volume":"13","author":"Speca","year":"2023","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500059633","article-title":"IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients","volume":"38","author":"Shoenfeld","year":"2005","journal-title":"Autoimmunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:219","article-title":"Intravenous immunoglobulin therapy and systemic lupus erythematosus","volume":"29","author":"Zandman-Goddard","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/antib12010020","article-title":"Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine","volume":"12","author":"Velikova","year":"2023","journal-title":"Antibodies (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1191\/096120399678841007","article-title":"A study of 20 SLE patients with intravenous immunoglobulin--clinical and serologic response","volume":"8","author":"Levy","year":"1999","journal-title":"Lupus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103710","article-title":"Intravenous immunoglobulin as a therapy for autoimmune conditions","volume":"24","author":"Danieli","year":"2025","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1949145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:36:38Z","timestamp":1791174998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1949145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1949145"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1949145","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"article-number":"1949145"}}